Case 2: 82-Year-Old Former Smoker with Poorly Differentiated Lung Adenocarcinoma and PD-L1 of 85%

Updated, comprehensive OS results with the combination in resectable NSCLC will be shared in a future peer-reviewed setting.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

IBI363 demonstrated encouraging efficacy and a manageable safety profile in patients with squamous NSCLC based on results from a phase 1 trial.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Radiotherapy plus camrelizumab and platinum-doublet chemotherapy showed manageable toxicity in untreated non–small cell lung cancer with brain metastases.

The diagnostic accuracy of radiologists aided by the eyonis LCS AI software was greatly improved compared with when radiologists were unaided.